Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 5/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | PDE6D | O43924 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4791797 | 0.89 | HTR2A (0.44) | HCRTR1HTR2AHCRTR2SLC6A9PDE6D | |
| SCHEMBL4773910 | 0.89 | HCRTR1 (0.43) | HCRTR1CCR3HTR2AHCRTR2SLC6A9 | |
| SCHEMBL4775700 | 0.86 | HCRTR1 (0.42) | HCRTR1CCR3HTR2AHCRTR2 | |
| SCHEMBL4768141 | 0.85 | HCRTR1 (0.44) | HCRTR1HTR2AHCRTR2 | |
| SCHEMBL4791290 | 0.85 | HCRTR2 (0.50) | HCRTR1HTR2AHCRTR2 | |
| SCHEMBL4771878 | 0.82 | HCRTR1 (0.44) | HCRTR1HTR2AHCRTR2 | |
| SCHEMBL4777235 | 0.78 | HCRTR1 (0.44) | HCRTR1HTR2AHCRTR2SLC6A9 | |
| SCHEMBL4771763 | 0.77 | KDM4E (0.44) | HCRTR1HTR2AHCRTR2SLC6A9 | |
| SCHEMBL4777203 | 0.77 | HCRTR1 (0.54) | HCRTR1HTR2AHCRTR2 | |
| SCHEMBL4775758 | 0.76 | FFAR4 (0.45) | HCRTR1HTR2AHCRTR2CYP2D6SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | claimed |
| EP-1871752-A1 | AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-01-02 | — | — | EP | claimed |
| WO-2006110626-A1 | AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-10-19 | — | — | WO | claimed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-10-23 | — | — | US | disclosed |
| WO-2006110626-A1 | AMIDOPROPOXYPHENYL OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262046-A1 | Amidopropoxyphenyl Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885CCR3 641/4885HTR2A 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.